{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=In+Expansion%3A+Melanoma%2C+Non-small+Cell+Lung+Cancer", "query": { "condition": "In Expansion: Melanoma, Non-small Cell Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=In+Expansion%3A+Melanoma%2C+Non-small+Cell+Lung+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T11:48:37.921Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04068896", "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Metastatic Castration-resistant Prostate Cancer", "Bladder Cancer", "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Ovarian Cancer", "Head Neck Squamous Cell Carcinoma", "Prostate Cancer" ], "interventions": [ { "name": "NGM120 30mg", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg", "type": "BIOLOGICAL" }, { "name": "NGM120 30mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg Q3W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-10-16", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068896" }, { "nct_id": "NCT04913337", "title": "Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Glioblastoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Melanoma", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Squamous Cell Carcinoma of Head and Neck", "Cholangiocarcinoma", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endocervical Cancer", "Colorectal Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "NGM707", "type": "DRUG" }, { "name": "NGM707 plus pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2021-06-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 20, "location_summary": "Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04913337" }, { "nct_id": "NCT02817633", "title": "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "TSR-022", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "TSR-033", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 463, "start_date": "2016-07-08", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 64, "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02817633" }, { "nct_id": "NCT05614102", "title": "A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BAY2965501", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum-based Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 284, "start_date": "2022-11-04", "completion_date": "2027-04-14", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 3, "location_summary": "Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05614102" }, { "nct_id": "NCT07115043", "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma (Skin)", "Renal Cell Carcinoma", "Merkel Cell Carcinoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer/Gastroesophageal Junction Cancer", "High Grade Serous Ovarian Carcinoma" ], "interventions": [ { "name": "AZD6750", "type": "DRUG" }, { "name": "rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-07-29", "completion_date": "2029-10-02", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 6, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115043" }, { "nct_id": "NCT06052852", "title": "Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Clear Cell Renal Cell Carcinoma", "Ovarian Cancer", "Head and Neck Cancer", "Colorectal Cancer", "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "BDC-3042", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bolt Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2023-10-11", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 6, "location_summary": "Palo Alto, California • Boston, Massachusetts • Austin, Texas + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Austin", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052852" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT06448364", "title": "A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Urothelial Cancer", "Melanoma" ], "interventions": [ { "name": "PF-07329640", "type": "BIOLOGICAL" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-05-09", "completion_date": "2024-08-15", "has_results": false, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 4, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06448364" }, { "nct_id": "NCT04261439", "title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "In Escalation: All Patients With Solid Tumors and Lymphoma", "In Expansion: Melanoma, Non-small Cell Lung Cancer" ], "interventions": [ { "name": "NIZ985", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-02-27", "completion_date": "2023-12-27", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 2, "location_summary": "Duarte, California • La Jolla, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04261439" }, { "nct_id": "NCT03504488", "title": "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Melanoma", "Head and Neck Cancer" ], "interventions": [ { "name": "CAB-ROR2-ADC", "type": "BIOLOGICAL" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2018-06-27", "completion_date": "2024-12-30", "has_results": false, "last_update_posted_date": "2025-01-15", "last_synced_at": "2026-06-07T11:48:37.921Z", "location_count": 38, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 30 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03504488" } ] }